2 334

Cited 16 times in

A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.

Authors
 Chong Kun Im  ;  Hei-Cheul Jeung  ;  Sun Young Rha  ;  Nae Choon Yoo  ;  Sung Hoon Noh  ;  Jae Kyung Roh  ;  Hyun Cheol Chung 
Citation
 CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.61(2) : 315-321, 2008 
Journal Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN
 0344-5704 
Issue Date
2008
MeSH
Adult ; Aged ; Antidotes/administration & dosage ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Female ; Fluorouracil/administration & dosage ; Hematologic Diseases/blood ; Hematologic Diseases/chemically induced ; Humans ; Infusions, Intravenous ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Neoplasm Metastasis ; Paclitaxel/administration & dosage ; Prognosis ; Stomach Neoplasms/drug therapy* ; Survival Analysis
Keywords
Paclitaxel ; Advanced gastric cancer ; 5-FU ; Leucovorin
Abstract
PURPOSE: The aim of this study was to investigate the efficacy and safety of the combination chemotherapy of paclitaxel, infusional 5-fluorouracil (5-FU) and leucovorin (FLT regimen) in advanced gastric cancer. The primary end point was the time to progression (TTP). METHODS: Patients with evaluable disease with or without measurable lesions received 175 mg/m2 paclitaxel on day 1 followed by 20 mg/m2 leucovorin and 24-h infusion of 5-FU 1,000 mg/m2 (day 1-3) repeated every 3 weeks. RESULTS: Sixty patients were enrolled. The median TTP and overall survival duration were 13 and 60 weeks, respectively. One-year survival rate was 53.3%. Of the 50 patients with measurable lesion, the overall response rate was 31.7%. The most common grade 3-4 adverse event was neutropenia (61.7%). CONCLUSION: The FLT regimen showed an efficacy comparable to other regimens of cisplatin or anthracycline combinations with the advantage of remarkably low non-hematological toxicity. These data about the efficacy of this regimen need confirmation in a phase III trial.
Full Text
http://link.springer.com/article/10.1007%2Fs00280-007-0508-6
DOI
10.1007/s00280-007-0508-6
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Roh, Jae Kyung(노재경)
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Yoo, Nae Choon(유내춘)
Im, Chong Kun(임종근)
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/106668
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links